We conducted a longitudinal retrospective analysis of TRAb bioactivity over a period of 9 48 years in 45 MS patients receiving ALTZ using available stored serum; 31 developed 49 thyroid dysfunction (TD) and 14 remained euthyroid despite being followed for a 50 minimum of 5 years (NO-TD). The presence of TRAb was evaluated at standardized time 51 points: A) pre-ALTZ, B) latest time available post-ALTZ and before TD onset, C) post-52 ALTZ during/after TD onset. Serum TRAb were detected by published in-house assays 53 (ihTRAb): flow cytometry (FC) detecting any TSHR-binding TRAb and luciferase 54 bioassays (LB) detecting TSAb/TBAb bioactivity. Purified IgGs were used to verify 55 TSAb/TBAb in selected hypothyroid cases. Standard clinical automated measurements of 56 TRAb (autTRAb), anti-thyroid peroxidase autoantibodies (TPOAb), thyroid stimulating 57 hormone, free-thyroxine and free-triiodothyronine were also collected. 58
RESULTS 59
Pre-ALTZ, combined ihTRAb (positive with FC and/or LB), but not autTRAb, were 60 present in 5/16 (31.2%) TD versus 0/14 (0%) NO-TD (p=0.017). Detectable ihTRAb
INTRODUCTION 73
Alemtuzumab (ALTZ; Campath-1H) is an anti-CD52 humanized monoclonal 74 which has proven efficacy in relapsing multiple sclerosis (MS) (1). It is administered as a 75 standard treatment regime (two cycles one year apart), with subsequent courses 76 determined by evidence of returning central nervous system inflammatory activity. It 77 causes rapid complement mediated lysis of circulating lymphocytes and profound 78 lymphopenia. Since bone marrow derived lymphoid precursors are unaffected, 79 lymphocyte reconstitution subsequently occurs, which appears to have a beneficial effect. 80
Patterns of lymphocyte re-population vary between patients but circulating B cells return 81 most rapidly and can rise to higher levels than baseline (2), whilst CD4/CD8 T cells 82 numbers recover more slowly, and may never attain pre-treatment levels (3, 4) . Despite 83 prolonged T cell lymphopenia post-alemtuzumab immune competence is largely 84 preserved and significant infections occur only rarely (5). However 30-48% of patients 85 develop secondary autoimmunity, mainly humoral, 0.5-11 years after treatment (peak 86 incidence 2-3 years) (6-10). The commonest disease (41%) is thyroid autoimmunity (TA) 87 (11), followed by idiopathic thrombocytopenic purpura (1-3%). However, a range of other 88 rare autoimmune disorders including haemolytic anaemia, neutropenia and Goodpasture 89 syndrome have also been reported (1, (12) (13) (14) . The exact pathogenic mechanism for post-90 ALTZ TA remains unclear, however it is considered to be an "immune reconstitution 91 syndrome", i.e. an autoimmune phenomenon occurring during or after a phase of immune 92 restoration following lymphopenia. This has also been reported in HIV patients following 93 antiretroviral therapy and after bone marrow transplantation (7, 8) . 94
Among TA, ALTZ predominantly induces Graves' disease (GD: 63%), followed 95 by hypothyroidism (34%), and rarely transient thyroiditis (11) . GD is caused by anti-96 thyrotropin (TSH) receptor (TSHR) autoantibodies (TRAb) persistently activating the 97 TSHR (TSHR-stimulating antibodies: TSAb), leading to hyperthyroidism (15) . TRAb can 98 also block the TSHR (TSHR-blocking antibodies, TBAb), causing hypothyroidism 99 (16, 17) , and "neutral" TRAb (which bind the TSHR without affecting thyroid function: 100 TNAb) have been reported in around 12% of subjects with normal thyroid function, 59-101 84% GD patients (depending on the assay type used), and patients with autoimmune 102 thyroiditis at lower rates (18) (19) (20) . TNAb seem to bind TSHR but do not activate the 103 cAMP signaling cascade, which is the principal pathway leading to thyroid hormones 104 synthesis; however they may be able to trigger alternative and multiple signaling cascades 105 having complex downstream effects, including oxidative stress (20) . 106
In spontaneous TA, TBAb account for a minority of cases of hypothyroidism 107 (around 9-10%) (16,21), the remainder being due to lymphocyte-mediated damaging of 108 the thyroid, as in classical Hashimoto's thyroiditis (22) . Autoantibodies to thyroid 109 peroxidase (TPOAb) are the hallmark of such autoimmune thyroiditis, however they are 110 very often positive in GD also, indicating that in TA the self-tolerance breakdown 111 involves multiple thyroid antigens (23) . Surprisingly, TRAb are positive in 50.0%-76.7% 112 of patients with post-ALTZ hypothyroidism (9,10), with TBAb representing a common 113 mechanism of post-ALTZ hypothyroidism in a recent analysis (10). 114
TPOAb are very common in the general population (up to 20%) (24,25), and have 115 been identified as a predictive marker of TD subsequent to ALTZ (9). In particular, 69% 116 of MS subjects TPOAb positive before ALTZ developed subsequent TD, compared to 117 31% of TPOAb negative subjects. However, 85% patients who later developed TD were 118
TPOAb negative at baseline, indicating that TPOAb status alone has limited value in risk 119 stratification in the majority of patients (9). 120
The longitudinal study of ALTZ-treated patients provides a rare opportunity to 121 study TRAb prevalence and biological function prior to disease "triggering" in patients 122 who develop GD. The automated TRAb assays (autTRAb) used in clinical diagnostics are 123 unable to distinguish TSAb/TBAb (26); as a result several groups including ours have 124 developed in-house bioassays able to detect TSAb (27, 28) and TBAb (21, 29) , as well as 125
TNAb (19). We postulated that TRAb, in particular TNAb, pre-existing before ALTZ 126 may be the precursors of the TSAb and TBAb that subsequently develop by somatic 127 hypermutation and affinity maturation in B cells (30, 31) . Detection of low titre or low 128 affinity TSAb/TBAb or the presence of TNAb prior to ALTZ therapy, in combination 129 with TPOAb testing, may also increase our ability to predict thyroid dysfunction after 130
ALTZ. 131
In addition we used the in-house TRAb bioassays (ihTRAb) to analyze TRAb 132 bioactivity arising after ALTZ therapy, which has so far only been described in 133 spontaneous TA (21, 28, 32) . In a recent UK study conducted in collaboration between 134
Cambridge and Cardiff we have introduced TSAb/TBAb analysis in post-ALTZ TA, 135 however this was limited to only a few patients affected with hypothyroidism or 136 "fluctuating" GD, defined as multiple alternate phases of hyperthyroidism and 137 hypothyroidism (10). In the present study we extended this analysis to all available cases, 138
including a third different in-house assay to detect TSHR-binding TRAb independently 139 from their bioactivity (19) . 140 Samples from 14 patients who had not developed TD (NO-TD) were also selected based 152 on the availability of serum before ALTZ, and clinical follow-up of ≥5 years, in order to 153 exclude cases of late TD onset (11). Sera from pre-specified time-points were requested 154 for TD and NO-TD groups (Figure 1 ): A) first available pre-ALTZ time; B) the latest time 155 available post-ALTZ and before the TD onset; C) post-ALTZ at the TD onset, or 156 alternatively the earliest subsequent time available (TD only). 157
MATERIALS AND METHODS
All patients were treated with ALTZ at the University Hospital of Wales (UHW) 158
in Cardiff, UK, and followed up both at UHW and local Welsh hospitals. ALTZ was 159 administered intravenously 5 consecutive days for the first cycle, with the majority of 160 subjects receiving a second cycle (3 consecutive days) 12 months later; in some patients 161 further doses were given at least one year apart, depending on clinical and radiological 162 outcomes. The date of the first ALTZ administration within our patient cohort ranged 163 In-house luciferase bioassays (LB) to detect TSAb and TBAb were performed 173 using a Chinese Hamster Ovary (CHO) cell line stably transfected with the human TSHR 174 and a cAMP responsive luciferase reporter (pA3Luc), as previously described (Lulu*) 175 (27, 29) . Briefly, cells were seeded at 2x10 4 cells/well in 96-well plates in Ham's F12 176 containing 10% fetal calf serum, and switched to Ham's F12 containing 10% charcoal 177 stripped calf serum the day before the assay. In the assays cells were incubated for 4 hours 178 at 37°C in 5% CO2 in air with whole human serum (1:10 dilution) in serum-free medium 179 (SFM: Ham's F-12 supplemented with 2.5% sodium bicarbonate) for the TSAb assay, and 180 SFM containing 1 mU/ml bovine TSH (bTSH; Sigma-Aldrich Company Ltd., Poole, UK) 181 in the TBAb assay. Cells were also incubated with SFM alone as negative control, and 5 182 mU/ml bTSH and 0.2 ng/μl M22 human monoclonal Ab to TSHR (RSR, Cardiff, UK) as 183 positive controls. Cells were finally lysed, and the luciferase activity measured using 184 commercially available kits (Promega, Madison, USA) and a luminometer machine 185 (Glomax®-Multi Detection System, Promega). 186
Randomly selected sera from 9 euthyroid participants from the Controlled 187
Antenatal Thyroid Screening II (CATS II) study (33, 34) were used as euthyroid pool in 188 both TSAb/TBAb assays; they were all adult women (mean age ± standard deviation = 189 40.8 ± 5.3 years) with normal thyroid function and negative for TPOAb. 190 In the TSAb assay, CHO cells transfected with pA3Luc only (Zulu) were used in 191 parallel to Lulu*. The considered positivity cut-off was a stimulation index (SI) >1.5 192 calculated with the following formula: The TBAb assay positivity cut-off was an inhibition index (InI) >20% as previously determined (formula A) (29) using Lulu* cultured with 1 mU/ml bTSH: 198 InI = 100 X (1light patient sample) 199 light euthyroid pool 200
In order to exclude interference of high serum TSH levels with our in-house 201 TSAb/TBAb serum assay, especially among hypothyroid patients, experiments were 202 repeated using IgG (amount equivalent to 1:10 serum dilution) in place of serum; if 203 results were discordant we counted those using IgGs. IgGs were purified from selected 204 serum samples with the Melon Gel IgG Purification Kit (Pierce, Rockford, IL) according 205 to the manufacturer's protocol. Briefly, serum samples were diluted 1:10 and the diluted 206 serum was added to a spin column containing the Melon Gel resin. After 30 minutes 207 incubation, the purified IgGs were collected in the flow through by centrifugation of the 208 spin column, and the IgG concentration measured by ultraviolet optical absorption at 280 209 nm with a NanoDrop TM Lite spectrophotometer (Thermo Scientific). All IgG purified 210 samples were promptly used for downstream analysis, or aliquoted and stored at -20 °C. 211
Flow Cytometry (TSHR-binding TRAb) 212
In order to reduce the high non-specific background staining due to human 213 antibodies recognizing and/or cross-binding to surface CHO proteins, a serum pre-214 adsorption step using Zulu cells was performed as previously described (35). 215
Flow cytometry (FC) detection of TSHR-binding TRAb (FC-TRAb) in pre-216 adsorbed sera was then performed using CHO cells expressing the 217 glycosylphosphatidylinositol (GPI)-anchored TSHR extracellular domain (CHO-TSHR), 218 as previously described (19) . As minor protocol modifications, 1:100 goat polyclonal anti- sample test was used to obtain the greatest difference between the two histograms, quoted 232 as D value (D) (36). Cut-off values were defined based on the mean D +2 SD of 233 individual pre-adsorbed sera from 9 healthy women from the CATS II study (33,34) used 234 as controls; all values higher than this were considered positive (FC-TRAb+) (35). 235
Automated Laboratory Measurements 236
Automated TRAb (autTRAb) were measured with the Brahms Diagnostika 237
Lumitest TRAK assay (Germany; Reference Ranges IU/L = Negative <1, Borderline 1-238 1.5, Positive >1.5) until January 2014, then using the Roche Cobas® e411 assay 239 (Switzerland; Reference Ranges IU/L = Negative <0.9, Borderline 0.9-1.6, Positive 240 >1.6). According to Thermoscientific, human TSH does not interfere with TRAb 241 measurement in the Lumitest TRAK assay, up to TSH values of at least 500mU/L. UHW 242 Biochemistry Department also run specific cross-reactivity tests using patient serum with 243 a TSH concentration of 179 mU/L, confirming no interference with neither Brahms nor 244
Roche TRAb assays. 245
TPOAb, TSH, FT4 and FT3 analyses were performed using an ADVIA Centaur 246 automated immunoassay analyser (Bayer plc, UK) until 31/05/2010, followed by Chemiluminescent Microparticle Immunoassay methods by the ARCHITECT® System 248 (ABBOTT Laboratories, USA) until the end of the observation period. Supplemental 249 Table 1 summarizes the changes of reference ranges occurred during this time period. 250
Definitions of Thyroid Function 251
All 45 patients included in the study were euthyroid when receiving the first 252 ALTZ treatment, and had no clinical history of thyroid disease. The time of TD onset was 253 defined as the first alteration of the thyroid function defined as persistent (i.e. detectable 254 in consecutive blood tests at least 3 months apart) and/or significant (i.e. requiring 255 immediate thyroid treatment). Hyperthyroidism was defined as low TSH with or without 256 raised FT4/FT3 levels; hypothyroidism was defined as raised TSH with or without low 257 FT4/FT3 levels. 
Statistical Analysis 270
According to the TRAb prevalence in the general population of 12% (19), our a 271 priori power calculation indicated 12 versus 12 subjects required to provide 80% power to detect a 5-fold TRAb prevalence (60%) in patients that will later develop ALTZ-induced 273 thyroid dysfunction, with a 0.05 significance level (two-tailed). Fisher exact test and t-test were used also to compare the characteristics of TD and 279 NO-TD groups, considering p<0.05 as significance level. 280
RESULTS 281
Patients 282
The Table 1 summarizes the characteristics of TD and NO-TD groups; no significant 287 differences were detected between the different groups. Before TD onset (time-points A 288 and B) all patients were euthyroid and free of persistent thyroid function abnormalities. 289
Note that at time-point C (TD group) many patients who developed thyroid dysfunction 290 were already on thyroid medication: a detailed description of their treatments and 291 outcomes has been reported elsewhere (10). 292
Combined in-house TRAb (ihTRAb) results at all time-points 293
We compared the overall results obtained with the three different ihTRAb assays 294 (FC-TRAb, LB-TSAb, LB-TBAb) at all time-points in TD and NO-TD groups. Due to the 295 retrospective nature of this study, sera from some time-points were unavailable for the TD 296 group (Table 1) . As shown in Figure 2 , at time-point A (before ALTZ) 5/16 (31.2%) TD 297 patients were found to be ihTRAb positive (ihTRAb+), compared with 0/14 (0%) NO-TD 298 patients (p=0.017). Following ALTZ, 6/25 (24.0%) TD patients were ihTRAb+ at time-299 point B (before TD onset); as expected, at time-point C (during or after TD onset) 300 ihTRAb+ cases markedly increased to 18/29 (62.1%). This prevalence is likely to be 301 underestimated, considering the late average collection time of time-point C compared 302 with disease onset (Table 1 ). Among NO-TD patients, 4/14 (28.6%) were ihTRAb+ at 303 time-point B. When splitting the overall ihTRAb+ results according to the TD subtype at 304 onset (hyperthyroidism or hypothyroidism), time-point A ihTRAb were predominantly 305 positive in those who subsequently developed hypothyroidism (4/6: 66.7%) rather than 306 hyperthyroidism (1/10: 10%), p=0.036. It is worth noting that two initially hypothyroid 307 ihTRAb+ patients subsequently showed a fluctuating thyroid function and were classified 308 as fluctuating GD. 309
Time-point A: predictors of post-ALTZ TD 310
To validate TRAb as an independent predictor of ALTZ-induced TD, we 311 compared ihTRAb results with autTRAb and TPOAb data at time-point A ( Considering this from a different perspective, TD developed in 7/7 (100%) 320 baseline ihTRAb and/or TPOAb positive patients, versus 9/23 (39.1%) baseline ihTRAb 321 and/or TPOAb negative patients (p=0.007). 322
AutTRAb were positive before ALTZ in only 1 patient of the TD hyperthyroid 323 subgroup (14.3%) and none in the hypothyroid group, suggesting that autTRAb do not 324 appear to be a useful predictive marker of subsequent TD development. 325 TNAb (3/5: 60%), defined as FC-TRAb+ but both LB-TSAb/TBAb negative (Table 3) . 331
In depth analysis of ihTRAb+ cases 326
At time-point B, ihTRAb+ cases were represented by a similar proportion of 332
TNAb, TSAb and TBAb (Table 3 ). In combination, TNAb or TSAb/TBAb preceded TD 333 onset in 9 cases (32.1%, considering a total of 28 TD patients with time-point A and/or B 334 available) with an interval before TD onset of a median of 1.2 years (range 28 days -7.3 335 years). 336
At time-point C (Table 3) , as expected all ihTRAb+ hyperthyroid GD and 337 fluctuating GD patients were also autTRAb+, confirming a GD diagnosis. Among 338 ihTRAb+ hyperthyroid and fluctuating GD cases, FC-TRAb was the most sensitive assay 339 with 13/14 (92.9%) positive, versus 9/14 (64.3%) of TSAb. TBAb were positive in 3/10 340 (30%) purely hyperthyroid ihTRAb+ GD patients. As expected fluctuating GD cases had 341 a documented TSAb/TBAb coexistence in 2/4 (50%) cases (IDs 35, 42) ; the other two 342 cases were positive for TSAb only (IDs 1, 7) .
Among the whole hypothyroid group (n=10), 4 (40%) were ihTRAb+ at time-point C, in 344 particular 2/4 (50%) FC-TRAb+ and 2/4 (50%) both FC-TRAb+ and TBAb+; autTRAb 345 results were concordant (Table 3) . Surprisingly, both ihTRAb+ hypothyroid patients at 346 time-point A (IDs 15, 37) resulted ihTRAb negative at time-point C. 347
Final thyroid diagnosis 348
TPOAb titres measured anytime post-ALTZ were available in 17/19 (89.5%) of 349 hyperthyroid group, and were positive in 15/17 (88.2%) cases; in fact two TPOAb 350 negative GD patients at time-point C ( Table 3) (12.9%) TRAb+ hypothyroidism, 3 (9.7%) chronic autoimmune thyroiditis, 2 (6.5%) 360 TPOAb+ subacute thyroiditis, 1 (3.2%) TPOAb-/TRAb-hypothyroidism. 361
DISCUSSION 362
We have described for the first time the biological function of TRAb in a 363 longitudinal cohort of patients developing ALTZ-induced thyroid dysfunction (TD) using 364 three different in-house TRAb assays (ihTRAb). Importantly, as a result of a structured 365 monitoring and sampling process for patients with MS in south Wales and suitable for 366 ALTZ treatment, serum was available before the onset of TD enabling us to describe how 367 and when TRAb become positive in patients with ALTZ-induced TD. This setting is 368 unique, as serum is not generally available before disease onset in sporadic GD. 369 Interestingly, serum ihTRAb, but not TRAb detected with standard automated assays 370 (autTRAb), were detected before ALTZ in one third of patients who later developed TD, 371 and in none of those who remained free of TD (NO-TD) over a minimum follow-up 372 period of 5 years. The appearance of ihTRAb was detected a mean of 1.2 years (range 28 373 days -7.3 years) prior to the development of thyroid dysfunction. We believe this is the 374 first report of the detection of TRAb prior to the onset of ALTZ-induced TD. Similar 375 findings have been previously described for spontaneous TD in a retrospective study 376
showing progressively increasing TRAb positivity, as well as TPOAb and anti-377 thyroglobulin antibodies, in patients who will later develop GD. In particular TRAb 378 positivity increased from 2% at 7 years before diagnosis to 55% at diagnosis, with 379 intermediate percentages of 7% and 20% at -5 and -2 years, respectively (38) . 380
Furthermore, in our study for the first time we provided details about TRAb 381 biological function over time. We have previously reported the presence neutral TRAb 382 (TNAb), detected using flow cytometry, in healthy euthyroid subjects, but without any 383 follow-up clinical data to indicate whether they later did develop TD (19). Information 384 similar to our data in ALTZ-induced disease are difficult to collect in the setting of 385 spontaneous autoimmune TD, requiring very large and long-term cohort studies. The fact 386 that the rates of TD post ALTZ are much higher than generally seen in MS, suggests that 387 the two settings are not necessarily comparable, however the principle that autoimmunity 388 to the TSHR may precede TD by many months or years applies to both ALTZ-induced 389 (this study) and spontaneous forms as reported by others (38) . Note that the wide range of 390 pre-TD intervals (28 days -7.3 years) is partly a consequence of the retrospective nature 391 of this study, not providing systematic and identical time-points for all patients. Future prospective studies are needed to precisely define how long ihTRAb may precede the 393 onset of TD in some cases. 394
In cases of TRAb positivity pre-dating TD, we hypothesize that TSHR-reactive B 395 cell clones may undergo progressive antigen-driven affinity maturation by somatic 396 hypermutation within germinal centres, and finally generate high affinity stimulating 397 (TSAb) or blocking (TBAb) TRAb. The phenomenon of multiple different pathogenic 398
TRAb arising from single B cell clones by somatic hypermutation has already been 399 described in mouse models of GD (30, 31) . In this context, our finding that ihTRAb more 400 commonly preceded hypo-than hyperthyroidism is interesting, but may reflect that once a 401 stimulatory TSAb-secreting clone develops, TD follows rapidly whereas it may take 402 longer for TBAb to achieve clinically relevant inhibition of thyroid function such that 403 TSH levels rise. Our observations are in accordance with previous evidence that TSAb are 404 potent at low concentrations, therefore inducing hyperthyroidism rapidly after their 405 appearance (23), while TBAb levels needed to trigger hypothyroidism are usually much 406 higher than TSAb levels inducing hyperthyroidism (26). Further prospective studies with 407 large numbers of subjects should clarify this. It also has to be mentioned that we did not 408 sub-classify TD patients into subclinical and overt disease since the vast majority of 409 patients diagnosed with subclinical disease went on to develop overt thyroid dysfunction, 410 or were treated immediately after diagnosis, preventing the possible evolution to overt 411
disease. 412
Although it is understandable that TNAb can exist without altering thyroid 413 However our findings show that around 40% of hypothyroidism post ALTZ is 451
TBAb mediated, as suggested in previous studies (9,10); this is nonetheless substantially 452 higher than reports in spontaneous disease (around 10%) (16, 21) . By contrast, 91.7% 453 (11/12) of hypothyroid subjects were TPOAb positive, consistent with TBAb negative 454 hypothyroidism post-ALTZ still being autoimmune in the majority of cases, but perhaps 455 cell-mediated. However, it was notable that autTRAb were detectable in many subjects 456 who developed hypothyroidism or a switching course as well as all those with 457 hyperthyroidism. Currently, autTRAb measurement is recommended only in patients 458 developing hyperthyroidism; if our observations are confirmed in larger prospective 459 studies, autTRAb testing should probably be extended to all cases of post-ALTZ TD, 460
including hypothyroidism, since they appear to predict a more complex clinical course 461 (i.e. possibility of thyroid function switching) requiring close observation. 462
The strength of our study is the long follow-up to define outcome (≥ 5 years where no 463 TD is reported) and the wide range of thyroid autoantibody assays used. However, ALTZ 464 has only recently been licensed for use in relapsing/remitting MS (since 2014) and hence 465 ALTZ-induced TD is currently not very common, especially cases with the long follow-466 up required to define outcome. As a result, our cohort is relatively small (n=45) and this is a limitation. Furthermore, due to the retrospective nature of the study, serum was not 468 available at all time-points in the whole cohort, and in particular, samples at the time of 469 TD onset were not always available. However we believe our finding that TRAb can 470 precede disease onset and are associated with subsequent TD is robust as our numbers 471
were consistent with our a priori power calculations. 472
473
In conclusion we have observed that TRAb can precede TD by many years and, if 474 present before ALTZ, can increase the risk of subsequent development of TD. Future 475 prospective studies are needed to determine the exact value of baseline and follow-up 476
TRAb testing in subjects treated with ALTZ and the most valuable assay to use. Such 477 studies, as well as large cohort studies in spontaneous thyroid autoimmunity may also be 478 used to investigate and define the process of affinity maturation in TRAb further. Now 479 that ALTZ is licensed for the treatment of relapsing/remitting MS in more than 60 480 countries, the available case load for prospective studies is likely to substantially increase 481 and make at least the studies in ALTZ induced disease feasible. 482
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developing any thyroid dysfunction (NO-TD). Below the dashed line TD patients were 695
further sub-grouped into hyperthyroidism (HYPER) or hypothyroidism (HYPO) as first 696 clinical manifestation. Numbers in brackets indicate the total number of available sera for 697 each time-point and patient subgroup. first TD defined as persistent (i.e. detectable in consecutive blood tests at least 3 months apart) and/or significant (i.e. requiring to immediate start a 714 thyroid treatment).
715
Fisher exact test (gender distribution) and t-test (other variables) excluded significant differences between the groups, when comparable (p= ns Cross-sectional results of all available sera at time-point A (before alemtuzumab treatment; see Figure  1 ) for autoantibodies to the thyrotropin receptor (TRAb) and autoantibodies to thyroid peroxidase (TPOAb), obtained in patients developing subsequent hyperthyroidism or hypothyroidism as first clinical manifestation, and patients not developing any thyroid dysfunction (NO-TD) following alemtuzumab treatment. White cells = negative TRAb/TPOAb results. Colored squares represent positive results: azure = TRAb detected by flow cytometry (FC-TRAb); green = stimulating TRAb detected by luciferase bioassays (LB-TSAb); purple = blocking TRAb detected by luciferase bioassays (LB-TBAb); grey = TRAb detected by automated systems (Aut-TRAb); yellow = TPOAb (automated assay); red = TRAb (any test) and/or TPOAb. NA = Not Available. * Fluctuating Graves' disease (GD) presenting hypothyroidism as first clinical manifestation. ★ TSH not available, but likely within the normal range, considering the evidence of stable euthyroidism for 5.9 years post-ALTZ.
753
Summary of autoantibodies to the thyrotropin receptor (TRAb), autoantibodies to thyroid peroxidase (TPOAb) and thyroid 754 stimulating hormone (TSH) status among patients positive for in-house TRAb assays (ihTRAb+). Only patients resulted ihTRAb+ in 755 at least one time-point are represented. 756
White cells = negative TRAb/TPOAb results. Colored squares represent positive results: azure = TRAb detected by flow cytometry 757
(FC-TRAb); green = stimulating TRAb detected by luciferase bioassays (LB-TSAb); purple = blocking TRAb detected by luciferase 758 bioassays (LB-TBAb); grey = TRAb detected by automated systems (AutTRAb); yellow = TPOAb (automated assay). 759 ALTZ = Alemtuzumab. GD = Graves' disease. ID = patient's identification number. NA = Not Applicable or Not Available. 760 TSH normal reference range varies between 0.30 -4.4 mU/L and 0.35 -5.5 mU/L, depending on the assay used and the date of test 761 (see supplemental table 1) . 762 α = Time (days) before onset of thyroid dysfunction 763 β = Time (days) after onset of thyroid dysfunction 764
Reference Ranges and Positivity Cut-offs 765
AutTRAb (IU/L) reference ranges: negative <1, borderline 1-1.5, positive >1.5 (until January 2014); negative <0.9, borderline 766 0.9-1.6, positive (from February 2014 onwards) 767
A,B = TPOAb (U/ml) reference ranges: A = negative <60, positive ≥60 (until May 2010); B = negative <6, positive ≥6 (from 768
June 2010 
